Longitudinal biospecimen & data collections

Longitudinal biospecimen collections capture the dynamic biology of disease by following individual patients over time—from diagnosis through treatment, remission, and potential relapse. These serial sample collections reveal temporal patterns invisible in cross-sectional studies, enabling research into disease progression, treatment response mechanisms, biomarker evolution, and emergence of therapeutic resistance. Understanding how disease states change within individual patients provides insights that cannot be obtained from single-timepoint specimens alone.

MT Group has achieved 95%+ patient retention rates in cancer longitudinal studies (excluding patients who pass away or enter hospice care) through proactive subject engagement, coordination with standard-of-care clinical visits, and experienced project management. High retention ensures complete datasets with minimal missing timepoints, maximizing statistical power and study validity. Whether tracking cancer patients through multi-modal therapy, monitoring autoimmune disease flares and remissions, or following metabolic disease progression, MT Group’s longitudinal biospecimen collection capabilities support diverse research objectives across therapeutic areas.

Understanding Longitudinal Biospecimen Studies

Longitudinal biospecimen studies involve serial sample collection from the same patients at multiple timepoints throughout their disease journey. Rather than comparing different patient groups at single moments, longitudinal studies track changes within individual patients over weeks, months, or years. This temporal disease tracking captures the dynamic nature of biology—how tumors evolve under treatment pressure, how immune responses wax and wane, how biomarkers fluctuate with disease activity.

Serial sampling frameworks typically include baseline collection before intervention, on-treatment monitoring at defined intervals, and outcome assessment timepoints. The power of longitudinal designs lies in paired analysis—each patient serves as their own control, reducing variability from genetic background, environmental factors, and inter-patient heterogeneity.

Why High Retention Rates Matter for Your Study

Patient retention directly impacts the quality and validity of longitudinal research. Missing timepoints create incomplete datasets that reduce statistical power, limit paired analyses, and introduce bias if patients who drop out differ systematically from those who remain. High retention rates preserve the fundamental advantage of longitudinal designs: within-subject comparisons that track individual trajectories and enable sophisticated temporal analyses.

MT Group achieves strong retention through systematic operational practices developed over hundreds of longitudinal collections. We coordinate research blood draws with standard-of-care clinical appointments, minimizing additional visits that burden subjects. Project management teams maintain proactive communication with subjects and sites, sending reminders before upcoming visits and quickly addressing scheduling conflicts. Flexible collection windows accommodate patients’ lives while maintaining protocol compliance.

Understanding Treatment Response Through Longitudinal Biospecimens

Longitudinal collections are particularly valuable for understanding treatment response patterns. Serial samples distinguish early responders from non-responders, identify biomarkers predicting therapeutic benefit, and reveal mechanisms of resistance in patients who initially respond but later progress. Perhaps most importantly, longitudinal specimens from non-responders enable research into why certain patients fail to benefit from therapies.

Understanding non-response biology helps identify patient populations for new drug candidates. If longitudinal biomarkers reveal that non-responders share specific molecular characteristics—pathway activations, immune profiles, or baseline disease features—these signatures can inform eligibility criteria for trials testing alternative mechanisms. Non-responder biospecimens become critical tools for developing therapies targeting unmet medical needs in populations poorly served by existing treatments.

Serial biomarker monitoring also captures pharmacodynamic effects over time, distinguishing on-target drug effects from disease progression, identifying optimal dosing through temporal biomarker trajectories, and detecting early resistance signals before clinical progression.

Collection Timepoints and Study Design Flexibility

MT Group designs longitudinal collection protocols around each disease’s clinical trajectory and research objectives. Collection timepoints are strategically placed to capture critical transitions while coordinating with standard-of-care visits when patients are already in clinic.

Cancer Longitudinal Timepoints:

• Screening: Biospecimens collected during routine screening procedures (colonoscopy, mammography, low-dose CT) before cancer diagnosis
• Diagnosis/Pre-Treatment Baseline: Specimens at diagnosis before any therapy, establishing baseline tumor biology
• Post-Neoadjuvant Therapy: Collections after pre-operative treatment but before surgery, assessing treatment response
• Post-Surgery: Specimens following surgical resection
• On Adjuvant Therapy: Serial collections during post-operative systemic therapy, monitoring treatment effects
• Remission/Surveillance: Regular collections during disease-free follow-up, tracking minimal residual disease
• Relapse/Progression: Specimens at disease recurrence, understanding resistance mechanisms

Customizable Collection Intervals:

Collection frequency is tailored to disease dynamics and research questions. Typical intervals include monthly collections during active treatment coordinated with infusion visits or clinic appointments, quarterly collections during maintenance or surveillance phases, and annual collections for long-term follow-up studies. All collections are coordinated with standard-of-care clinic visits to minimize subject burden and support retention.

Disease-Specific Longitudinal Collection Capabilities

Solid Tumors

Solid tumor longitudinal collections track patients from diagnosis through multi-modal therapy and surveillance. Blood specimens are collected at baseline, during chemotherapy cycles, at radiologic response assessments, and throughout long-term follow-up. Serial collections capture circulating tumor DNA dynamics, immune cell profiles, cytokine patterns, and other biomarkers reflecting tumor burden and treatment response. These longitudinal datasets support research into early response prediction, minimal residual disease monitoring, and mechanisms of acquired therapeutic resistance.

Autoimmune and Inflammatory Diseases

Autoimmune disease longitudinal collections track patients through treatment algorithms as therapies are initiated, escalated, or switched. For atopic dermatitis, typical timepoints include diagnosis, on first-line topical therapy, after escalation to systemic agents, on biologic therapy, and during maintenance. For inflammatory bowel disease, collections occur at diagnosis, during acute flares, after treatment escalation to biologics, and during clinical remission. These blood-based longitudinal samples enable research into treatment response biomarkers, mechanisms of biologic efficacy, and predictors of long-term disease control.

NASH and Metabolic Disease

NASH longitudinal studies follow disease from diagnosis through management strategies including lifestyle interventions and emerging therapeutics. Collections occur at baseline diagnosis, during weight loss programs, on pharmacologic interventions, and at follow-up assessment timepoints. Serial blood specimens track non-invasive biomarkers—liver enzymes, fibrosis markers, metabolic panels—supporting development of blood-based tests to monitor NASH progression.

Research Applications for Longitudinal Samples

Treatment Response Prediction and Monitoring

Early timepoint biomarkers predict later treatment outcomes, enabling identification of likely responders versus non-responders. Longitudinal studies identify which measurements at early visits forecast responses at later timepoints, potentially guiding treatment selection or early discontinuation of ineffective therapies.

Minimal Residual Disease Tracking

Sensitive detection of residual disease after treatment predicts relapse before clinical recurrence. Longitudinal monitoring of circulating tumor DNA, cancer-associated mutations, or disease-specific biomarkers tracks minimal residual disease levels over time, potentially enabling earlier intervention.

Biomarker Discovery and Validation

Longitudinal samples enable identification of biomarkers that change with disease state or treatment response. Serial measurements distinguish fluctuating markers from stable traits, identify early response signals, and validate candidate biomarkers against longitudinal clinical data.

Drug Resistance Mechanisms

Serial specimens from patients progressing on therapy reveal molecular changes conferring resistance. Comparing baseline and progression biospecimens identifies acquired mutations, pathway activations, or immune escape mechanisms developing under treatment pressure.

Real-World Evidence Generation

Longitudinal collections in community practice settings capture real-world treatment patterns, outcomes, and biomarker dynamics outside controlled clinical trials. These datasets complement trial evidence and support understanding therapeutic effectiveness in broader patient populations.

Biospecimen Types for Longitudinal Studies

Blood is the primary specimen type for longitudinal studies due to minimally invasive collection during routine clinical visits. Whole blood, plasma, serum, and buffy coat are collected at each timepoint, processed consistently using standardized protocols to minimize batch effects across serial collections. Specialized tubes including PAXgene RNA tubes, Streck cfDNA tubes, and standard anticoagulants are selected based on analytical endpoints.

Urine, saliva, stool, and other minimally-invasive specimens complement blood collections in disease-specific longitudinal studies when relevant to research objectives. All specimens are collected at coordinated timepoints with consistent processing to ensure comparability of serial measurements.

Clinical Metadata Captured Longitudinally

Comprehensive clinical annotation at each collection timepoint provides context for interpreting biospecimen findings:

Treatment Documentation – Every medication change including drug names, doses, start and stop dates, and reasons for modifications. Chemotherapy cycles, radiation courses, surgical procedures documented with dates.

Disease Assessments – Disease severity measured using validated scoring systems—tumor measurements, disease activity scores for autoimmune conditions, fibrosis staging for liver disease.

Laboratory Values – Standard-of-care laboratory results including blood counts, metabolic panels, and disease-specific markers captured at each visit.

Imaging Results – Radiologic assessments with tumor measurements and interpretations documented to anchor response assessments.

Adverse Events – Treatment-related toxicities captured with severity grades, onset timing, and resolution.

Clinical Outcomes – Long-term outcomes including overall survival, progression-free survival, and disease-specific events tracked throughout follow-up.

Frequently Asked Questions

What patient retention rates do you achieve for longitudinal studies?

MT Group has achieved 95%+ patient retention rates in cancer longitudinal studies, excluding patients who pass away or enter hospice care. Retention rates vary by disease state, study duration, and collection intensity. We achieve strong retention through coordinating research collections with standard-of-care clinic visits, proactive communication and scheduling with subjects throughout the study, flexible collection windows accommodating patients’ schedules, and experienced project management dedicated to longitudinal study execution. During feasibility assessment, we provide realistic retention projections based on your specific disease state and study design.

What collection intervals are available for serial sample collection?

Collection intervals are coordinated around standard-of-care clinical visits and customized to disease dynamics and research objectives. Monthly collections work well during active treatment when patients have regular clinic appointments. Quarterly collections are common for maintenance therapy or surveillance phases. Annual collections support long-term follow-up studies. Collection timing can accommodate treatment schedules and clinical assessment timepoints relevant to your research questions.

Can you design custom longitudinal collection protocols for specific research needs?

Yes, every MT Group longitudinal collection is customized to specific research requirements. We work with you during study design to define optimal timepoints capturing critical disease transitions, determine appropriate collection intervals balancing research needs with patient burden, select biospecimen types and processing protocols aligned with analytical endpoints, and identify clinical data elements necessary for correlative analyses. Custom protocols ensure longitudinal collections align precisely with scientific objectives.

What disease areas are supported for longitudinal biospecimen collection?

MT Group has extensive experience with longitudinal collections across solid tumors (lung, breast, colorectal, pancreatic, prostate, melanoma, and others), autoimmune diseases (psoriasis, atopic dermatitis, inflammatory bowel disease), and metabolic diseases (NASH, diabetes, obesity). Our multi-specialty site network enables longitudinal studies in virtually any disease state where patients have regular clinical follow-up.

How do you handle missed collection timepoints in longitudinal studies?

We implement collection windows (e.g., ±1 week around target dates) allowing scheduling flexibility while maintaining protocol compliance, coordinate make-up collections at next available clinic visits, and maintain proactive communication with subjects before scheduled visits to reduce no-shows. For subjects who permanently discontinue, we collect withdrawal samples when possible and document reasons for dropout.

What clinical annotations are captured at each longitudinal timepoint?

Clinical documentation at each collection includes current treatments with any modifications, disease assessments using validated scoring systems or imaging, laboratory results from standard-of-care testing, adverse events or toxicities, and updates to medical history. For cancer studies, response assessments or disease-specific criteria are documented. This longitudinal clinical data enables correlating biomarker changes with disease trajectories and clinical outcomes.

What is the maximum study duration supported for longitudinal collections?

MT Group has successfully executed longitudinal studies extending multiple years. Cancer surveillance studies have followed patients several years post-treatment, and chronic disease studies track patients through multi-year treatment courses. Study duration is determined by disease natural history and clinical follow-up patterns. Our retention strategies scale to extended durations through sustained subject engagement and coordination with evolving clinical care.